Celyad Oncology Return on Equity

Celyad Oncology (CYAD) currently reports a ROE of -437.12%. That is below the Healthcare sector average of 29.33%. Use the charts on this page to explore Celyad Oncology's ROE history and peer comparisons.

Celyad Oncology's ROE of -437.12% is lower than the Healthcare sector average of 29.33%. That is roughly 1590.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Celyad Oncology's current -437.12% should be judged against Healthcare norms (sector average: 29.33%) and against CYAD's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -437.12%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Celyad Oncology, and consider following CYAD for alerts when major investors trade the stock.

Celyad Oncology is classified in the Healthcare sector. On ROE, it currently shows -437.12% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYAD with unrelated industries.